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A preliminary clinical experience suggested tazarotene, a new acetylenic retinoid, as an effective alternative topical
treatment of basal cell carcinomas (BCC). The mechanisms of action of this synthetic retinoid, however, have not
been yet clariﬁed. In this work we assessed the in vivo effects of daily application of tazarotene for 24 wk, on 30
small superﬁcial and nodular BCC, and the in vitro effects of tazarotene on immortalized basal and squamous
tumor epidermal cells. Cellular proliferation, apoptosis and changes in expression of retinol and retinoic acid
receptors (RAR), p53, bcl-2, and bax were studied by immunohistochemistry, western blotting and PCR. Overall,
76.7% of treated tumors showed 450% regression. Complete healing was observed in 46.7% of all treated BCC,
without recurrences at 2-y observation. Regression was associated with reduced proliferation and increased
apoptosis, demonstrated by Ki-67- and TdT-mediated dUTP-biotin nick-end labelling-positive nuclear staining, and
with enhanced RAR-b and bax expression, with RAR-a and -c expression unchanged. In vitro, tazarotene induced a
concentration-dependent increase of RAR-b and bax associated with a greater rate of apoptosis and growth
inhibition in basaloid tumor cells compared with squamous tumor cells. Our studies provide convincing evidence
that tazarotene induces BCC regression possibly by synergistic RAR-b-dependent anti-proliferative and pro-
apoptotic pathways.
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Previous studies have described the effects of retinoids on
proliferation and differentiation of normal and neoplastic
cells and tissues, including the skin (Lotan and Gudas,
1994; Lotan, 1996). Tazarotene is an acetylenic retinoid
recently approved for treating heterogeneous skin disorders
such as psoriasis, acne, and photoaging. Cutaneous
application is neither teratogenic nor carcinogenic, and
tazarotene is not a sensitizing, phototoxic, or photosensitiz-
ing agent (Chandraratna, 1998). Although experimental
details concerning anti-cancer activity have been reported
(Thacher et al, 2000), the modalities of tazarotene-induced
regression of human cancers are unclear. Tazarotene acts
through its free-acid form, tazarotenic acid, to bind
selectively to retinoic acid receptors (RAR)-b and -g
isotypes (Nagpal and Chandraratna, 2000), but it is not yet
defined how RAR-b or other receptors contribute to the
overall growth inhibition induced by retinoids (Xu et al,
1997).
Preliminary clinical experience suggested tazarotene
may be an effective alternative option for the treatment of
cutaneous basal cell carcinomas (BCC) (Peris et al, 1999).
The aim of this study was to investigate the possible
mechanisms of action of tazarotene on BCC regression in
vivo during 24 wk of therapy and in vitro using histological,
immunohistochemical, and biomolecular methods. Tazaro-
tene-associated anti-proliferative and pro-apoptotic activ-
ities are reported and discussed in order to better
characterize the effectiveness of this retinoid in the topical
therapy of selected cases of BCC.
Results and Discussion
Regression was observed in 76.7% of treated BCC.
Complete healing was observed in 46.7% of all treated
BCC, in particular in 50% of superficial and in 40% of
nodular subtype of BCC. No recurrences were observed in
those BCC that healed completely after 2 y. Biopsies
obtained after 12 wk of tazarotene application showed
small areas of central necrosis in 30% of tumors (Fig 1A);
necrosis was absent in untreated control BCC. A dermal
lymphocytic infiltrate with abundant plasma cells was
focally present around basaloid cell aggregates; by con-
trast, inflammatory cells were scarce or absent in control
BCC (data not shown).
Proliferative activity evaluated by Ki-67 nuclear positivity
(Fig 1B) was lower in treated BCC (11.5%þ1.4%) com-
pared with controls (28.7%þ2.9%, po0.001). Immunor-
eaction for p-53 was heterogeneous and was detected in
23.3% of BCC overall, with no difference between treated1A. O. and L. B. equally contributed to the work.
Abbreviations: BCC, basal cell carcinomas; CRBP-1, cellular
retinol binding protein-1; RAR, retinoic acid receptors; TUNEL,
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tumors and controls. Quantification after TUNEL (Fig 1C)
showed increase of apoptotic nuclei in treated BCC
(4.45%þ1.12%) compared with controls (0.99%þ0.4%,
po0.01). Double immunostaining confirmed the epithelial
nature of the majority (490%) of TUNEL-positive nuclei.
Superficial and nodular BCC did not show any substantial
differences regarding apoptosis and proliferative rate (data
not shown).
Immunohistochemistry also revealed positive RAR-a and
-g reactions in control BCC, whereas RAR-b staining was
very faint (Fig 1D). Among control BCC, bax expression was
absent in 26.7% of tumors; when present, bax immunor-
eaction was weak and focal (Fig 1E). At week 12,
tazarotene-treated cells showed an increase in RAR-b
expression, which was progressively more conspicuous
moving towards the apoptotic areas (Fig 1F). A marked
enhancement of bax immunostaining, with a more diffuse
staining of both basaloid and palisade cells, was observed
(Fig 1G).
In vitro, tazarotene inhibited cell growth more in C5N
than in B9 cells (Fig 2A, po0.05). Tazarotene at various
concentrations does not reduce [H3]-thymidine incorpora-
tion in normal mouse keratinocyte cultures (Xiao JH and
Chandraratna R, personal communication). Tazarotene
inhibited AP1 transcriptional activity in a concentration-
dependent manner in CN5 and B9 cell lines (data not
shown), indicating that retinoid pathways leading to
modulation of AP1 activity were intact. As shown in Fig
2B, tazarotene increased apoptosis much more in C5N than
in B9 cells (po0.01 at 5 mM concentration).
Figure 1
In vivo and in vitro tazarotene-induced regression: (A) BCC biopsy
after 12 wk of topical treatment with 0.1% tazarotene. Basaloid cell
aggregates with a small area of central necrosis (white head arrow) and
a surrounding moderate dermal lymphoid infiltrate. Immunohistochem-
ical stains showing a small number of Ki-67-positive cells after (B) and
increased number of apoptotic cells as demonstrated by TUNEL (C)
after 12 wk of treatment with tazarotene. RAR-b (D) and bax protein
expression (E) is low or absent in control BCC and increased in tumor
biopsies after 12 wk of treatment with tazarotene (F, G). (H) Western
blots demonstrate the increase of RAR-b, bax, and caspase-3 cleavage
products in C5N but not in B9 cells treated for 48 h with 5mM tazarotene
(Taz), whereas RAR-a and -g, CRBP-1, bcl-2, and control b-actin levels
are unchanged. (I) Ladder production after blunt-end linker ligation PCR
of 1 mg genomic DNA in B9 and C5N cells. Treatment with 5 mM
tazarotene for 48 h increases apoptotic ladder much more in C5N than
in B9 cells. MW; fX174 DNA markers from Sigma (D-0672). (J)
Concentration-dependent increase of RAR-b in C5N cells cultured for
48 h in the presence of different concentrations of tazarotene (taz).
Figure2
Effect of tazarotene on growth inhibition and apoptosis: (A)
tazarotene-induced growth inhibition in B9 and C5N cultures. At higher
concentrations, tazarotene (taz) induces growth inhibition in a greater
percentage of C5N than B9 cells (p¼0.05). (B) Pro-apoptotic effect of
tazarotene in B9 and C5N cultures. Five mM tazarotene (taz) for 48 h
induces a greater percentage of apoptotic cells in C5N cultures
(p¼ 0.01).
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Western blotting showed a low level of RAR-b expression
in both control cultures (Fig 1H) and a concentration-
dependent increase in RAR-b expression in C5N cells
treated with tazarotene, but not in tazarotene-treated B9
cells (Fig 1J). Densitometric scanning of blots revealed that
C5N cells expressed more RAR-g and CRBP-1 than did B9
cells (po0.05). These levels were not modified by the
therapy, except for a slight increase of CRBP-1 expression
in B9 cells (189%þ25% of control), suggesting that
changes of these nuclear and cytoplasmic retinoic recep-
tors are not involved in tazarotene action on C5N cells. In
addition, at 5 mM of tazarotene concentration, bax expres-
sion increased markedly in C5N cells (321%þ30%,
po0.01), whereas bcl-2 level was unchanged (Fig 1H).
Densitometric analysis also showed an increased integrated
optical density of cleavage products of caspase-3 in treated
C5N cells (185%þ 30% of control, po0.02), but not in B9
cells. Densitometric analysis of products after ligation-
mediated PCR (Fig 1I) confirmed the greater presence of a
DNA apoptotic ladder in C5N cells than in B9 cells following
treatment with 5 mM tazarotene (po0.01). Apoptotic ladders
were scarce in both control cultures.
Our study documents that tazarotene-induced BCC
regression is associated with synergistic anti-proliferative
and pro-apoptotic pathways in basaliomatous cells in vivo.
Retinoids can be used as chemopreventative agents
because of their complex effects on proliferation, differ-
entiation, and apoptosis in normal and malignant cells, with
mechanisms varying according to cell phenotype and
culture conditions (Orlandi et al, 2001). Natural and
synthetic retinoids have shown their efficacy in inhibiting
tumor cell progression in a wide variety of experimental
models (Sun et al, 2000a, b). The action of retinoids in
human skin depends on the expression and modulation of
specific receptors. RAR-a and -g are normally detected in
the stratum granulosum, suggesting a function of these
isotypes in the switch from proliferation to differentiation of
keratinocytes, whereas the presence of b isotype in the
stratum granulosum is not appreciable (Reichrath et al,
1997). An earlier study showed that solid basaliomatous
aggregates in untreated BCC were markedly immunoposi-
tive for RAR-a and to a lesser extent for RAR-g, but showed
no staining or negligible staining for RAR-b (Kamradt and
Reichrath, 1996). In the study described here, tazarotene-
induced growth arrest was associated with enhancement of
RAR-b expression. Although an incidental induction could
not be excluded, our findings are consistent with those of
others (Khuri et al, 2000; Sun et al, 2000a, b) in supporting
the hypothesis that RAR-b plays a key role as a mediator of
tazarotene action by modulating growth in cells showing a
basaloid phenotype.
It is well known that retinoid-induced RAR-b expression
is an early step in the cascade of events leading to growth
inhibition (Sun et al, 2000a, b). Suppression of RAR-b has
been reported in head, neck, and lung carcinogenesis (see
also below), whereas RAR-a and -g are usually not altered
in vivo and in vitro in tumor cells (De Luca, 1991; Gebert
et al, 1991; Khuri et al, 2000). Moreover, RAR-b transfection
in RAR-b-negative tumor cell lines increases the respon-
siveness to retinoid-induced growth inhibition (Si et al, 1996;
Li et al, 1998) and experimental partial RAR-b inactivation
pre-disposes mice to lung cancer (Berard et al, 1996).
These data seem to support the hypothesis that the effects
of tazarotene are at least partially related to the presence of
a retinoic acid response element in the RAR-b gene
promoter (Sucov et al, 1990).
Although different signaling pathways may be (in)acti-
vated after tazarotene treatment, we observed in vitro a
greater cell growth inhibition in treated basal keratinocytes,
C5N cells, than in B9 cells. These latter cells display a
squamous differentiation phenotype, with no induction of
RAR-b or bax by tazarotene. This suggests that mechan-
isms other than RAR-b induction are involved in B9 cell
growth inhibition, and further studies are needed to
investigate the action of tazarotene in this squamous cell
line. This observation is in agreement with the resistance to
tazarotene of squamous cell carcinomas in vivo (Bianchi
et al, unpublished observations). Our results also confirm
that both control and treated BCC show generally low or
absent p53 immunoreactivity (Barrett et al, 1997), suggest-
ing that RAR-b upregulation is p53-independent.
We also investigated the possible role of retinoid
cytoplasmic receptors, in particular CRBP-1. Because of
its high-affinity for retinol and derivatives, CRBP-1 is
considered a chaperone-like molecule regulating the
pre-nuclear phase of retinoid signaling (Ong et al, 1994).
CRBP-1 expression is related to the transcriptional effect of
retinoids, mediated through the binding of RAR-a to the
CRBP-1 promoter (Husmann et al, 1992). Changes in
CRBP-1 expression were not associated with modulation
of cell cycle in treated BCC, confirming that tazarotene
affects proliferation and apoptosis through a different
pathway.
Our results also document a significant pro-apoptotic
activity of tazarotene in BCC cells in vivo as well as in basal
keratinocytes in vitro. Although a preliminary description of
similar effect in other tumors has been reported (Li et al,
1998), the pathway of tazarotene-related apoptosis in vivo is
unclear. Members of the bcl-2 gene family are the main
regulators of apoptosis but their role in the BCC apoptotic
pathway has not yet been elucidated. Bcl-2 promotes
survival, whereas bax induces death of cells (Huang et al,
1998). Bax protein forms homo- and heterodimers with bcl-
2 protein, and the ratio of bcl-2 to bax determines cell fate.
In untreated BCC, bax expression was low or undetectable,
confirming previous reports (Tomkova et al, 1998). In
tazarotene-treated BCC and C5N cells, apoptosis was
associated with an increased ratio of bax to bcl-2 due to
overexpression of bax, with bcl-2 levels unchanged. The
induction of bax is p53-independent in BCC, in contrast to
other tumors (Miyashita et al, 1994). Additional apoptotic
signals could modulate the tazarotene-induced apoptotic
pathway in vitro, in particular the cleavage of caspase-3.
The latter induces proteolytic cleavage of nuclear enzymes
(Yin et al, 1999), and the role of caspase-3 in the apoptotic
process has sometimes been associated with overexpres-
sion of bax (Orlandi et al, 2001).
Our results cannot exclude the possibility that tazarotene
may act in BCC through other cooperative apoptotic
pathways. Although in vitro studies support the direct pro-
apoptotic effect of tazaratone, an additional activity may be
the triggering of an immune response against tumor cells
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in vivo. We observed a chronic inflammatory infiltrate rich in
T lymphocytes and plasma cells surrounding and some-
times infiltrating the tumor islands. It is well known that BCC
lack an effective tumor-specific host T cell mediated
immune response, and this deficiency is demonstrated by
the efficacy of immune response modifiers (Urosevic and
Dummer, 2002). It is likely that a modulation of immune
response and/or immunogenicity in vivo may contribute to
increase apoptosis and/or necrosis. Retinoids promote and
modulate inflammation and the host immune response
(Thacher et al, 2000). Therefore, it could be also speculated
that tazarotene may have a pro-apoptotic effect by
restoring T cell response, possibly by modifying the
expression of chemoattractants and inflammatory cell
activators on the cell surface of BCC tumor cells (Toulouse
et al, 2000).
Materials and Methods
Patients Twenty superficial and 10 nodular BBC, ranging from 0.5
to 2 cm in maximum diameter, observed in 26 patients (aged 43–87
y, average 64.6þ 12.1), were diagnosed by clinical and dermo-
scopic diagnostic features and confirmed by histological examina-
tion of biopsy specimens. Tazarotene (AGN 190168; ethyl 6-[2-(4,4-
dimethylthiochroman-6-yl)-ethynyl] nicotinate), 0.1% gel, was
locally applied, once a day, at night, for 24 wk. Informed consent
was obtained from all patients, who were examined monthly with
clinical, photographical, and dermoscopical documentation. Re-
gression was defined as 450% clinical reduction of both diameter
and thickness of the neoplasm. Biopsies were obtained after 12
and 24 wk of treatment. At the end of the treatment period,
unresponsive BCC were surgically removed. The control lesions for
comparison were untreated BCC (n¼ 10) of the same histological
subtype and with similar clinical features, including site, that had
been surgically removed during the same period from patients
matched in age with the treated patients (data not shown).
Histology, immunohistochemistry and TUNEL Biopsies and
excisional samples were divided in two parts, the first frozen in
isopentane cooled in liquid nitrogen, the other fixed with 4%
paraformaldehyde in 0.1 M phosphate buffer (pH 7.3) and
embedded in paraffin. Serial cryostatic or 4-mm-thick paraffin
sections were stained with hematoxylin–eosin or used for
immunohistochemistry. For the latter, cryostatic sections, including
positive and negative controls, were first treated with H2O2 (20 min)
to block endogenous peroxidase activity and incubated with
normal goat serum (30 min), and then were reacted at room
temperature (30 min) with rabbit polyclonal anti-RAR-a, -b and -g
antibodies (1:100, Santa Cruz Biotechnologies, Inc, California).
Paraffin sections were processed similarly until the antibody
reaction step. Before incubation of sections, heat-mediated
antigen retrieval was performed with a solution 10 mM sodium
citrate buffer (pH 6.0) in a microwave oven (three cycles of 5 min).
Sections were then reacted with rabbit polyclonal anti-cellular
retinol binding protein-1 (CRBP-1, 1:100, a kind gift from Prof G.
Gabbiani, Geneva, Switzerland), or alternatively with monoclonal
antibodies to the following proteins: p53 protein (1:20), bcl-2 (1:40),
Ki-67 (Mib-1, 1:25) and CD3 (1:20, Ylem, Italy), bax protein (1:100,
Santa Cruz), CD20 (1:75) and CD68 (1:150, DAKO), CD4 and CD8
(1:50, Novocastra Laboratories Ltd, UK). Sections were then
reacted with biotinylated horse anti-rabbit or anti-mouse immu-
noglobulins (Vector) for 30 min and stained using the avidin–biotin
complex horseradish peroxidase method with diaminobenzidine as
chromogen.
For evaluation of apoptosis, rehydrated paraffin sections were
stripped of proteins by incubation with 300 U per mL of proteinase
K (Sigma-Aldrich, Italy) for 15 min at 371C. Endogenous peroxidase
was blocked by incubation with 0.1% H2O2 in methanol (20 min)
at room temperature. Apoptotic nuclei were revealed by TdT-
mediated dUTP-biotin nick-end labelling (TUNEL) (Gavrieli et al,
1992), with positive tissue controls. To confirm the epithelial nature
of apoptotic cells, we performed a double immunohistochemistry
with anti-AE1-AE3 cytokeratin antibody (1:50, Ylem).
In vitro studies Immortalized basal keratinocyte (C5N) and
squamous epidermal (B9) tumor cell lines (both cell lines were
kindly gifted from Dr Balmain and his co-worker Dr Han, UCSF, San
Francisco, California; Zoumpourlis et al, 2000) were grown in
monolayer culture in DMEM containing 10% calcium-free fetal
bovine serum. Cells seeded in six-well plates were treated with
tazarotene at different concentrations or with different concentra-
tions of DMSO (0.01%–0.1%) as controls. Cells were treated again
with tazarotene in fresh medium on day 4. On day 7, cells were
washed several times in phosphate-buffered saline (PBS), fixed
and stained with crystal violet. After several washes in PBS, crystal
violet was extracted with 10% acetic acid solution and cell viability
was evaluated using optical density. The percentage of growth
inhibition was calculated using the equation (1At per Ac)3 per
100, where At and Ac represent the absorbance in treated and
control cultures, respectively.
Cells were co-transfected with the COL-AP-1-LUC reporter
plasmid (a generous gift of Dr Karin, UCSD, San Diego, California),
encoding the luciferase gene controlled by a collagenase gene
promoter fragment containing a consensus AP-1 binding se-
quence, and the pRL-null plasmid encoding renilla luciferase
(Promega, Madison, Wisconsin) using Lipofectamine plus transfec-
tion reagent (Invitrogen) following the manufacturer’s protocol.
Relative luciferase activity was determined using the Dual-
Luciferase Assay System (Promega) using a luminometer and
normalizing values to renilla activity. To evaluate the ability of
tazarotene to induce apoptosis in vitro, sparse cultures were
treated with 1 or 5 mM tazarotene for 48 h. After Hoechst staining
for 15 min at room temperature, cells were analyzed by fluo-
rescence microscopy under UV light visualization. Cells displaying
nuclear features of apoptosis (chromatin condensation, fragmen-
tation, or shrinkage) were counted in triplicate as previously
reported (Orlandi et al, 2001).
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
and western blotting Sodium dodecyl sulfate-polyacrylamide gel
electrophoresis of cell extracts (Towbin et al, 1979) was performed
on a 5%–20% gradient gel stained with Coomassie Brilliant Blue (R
250, Fluka). For western blotting (Orlandi et al, 1994), 2–50 mg of
proteins were separated by electrophoresis, transferred to nitro-
cellulose filters (0.45 mm, Schleicher & Schuell), incubated with
rabbit polyclonal anti-RAR-a, -b and -g (1:100), bax and bcl-2
protein antibodies (1:100, Santa Cruz) followed by a goat-anti-
rabbit IgG (1:105, Santa Cruz). Enhanced chemiluminescence was
used for detection (Amersham). Quantification of Omat-x Kodak
films was performed as previously reported (Orlandi et al, 1994),
and repeated in triplicate.
DNA isolation and ligation-mediated PCR To better identify and
quantify DNA fragmentation associated with apoptosis in vitro, we
used ligation-mediated PCR of blunt DNA ends. Cells were
scraped, pelleted, frozen in liquid nitrogen, re-suspended in
0.5 mL of digestion buffer (70 mM NaCl, 10 mM Tris–HCl pH 8.0,
25 mM EDTA and 1% SDS) with 0.2 mg per mL proteinase K
(Sigma), and incubated overnight at 371C. Ligation-mediated PCR
of genomic DNA (1 mg) and quantification of nucleosomal ladders
in 15 mL aliquots of PCR products were performed in 1.2%
electrophoretic agarose gels stained by ethidium bromide (1 mg per
mL) as previously reported (Orlandi et al, 2001) and repeated in
duplicate.
Statistical analysis Statistical analysis was performed using the
SPSS program (Statistical Package for the Social Sciences, 5th
edn., MJ Norusis/SPSS Inc, Chicago, Illinois). For each parameter
1040 ORLANDI ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
the mean, standard error of mean and range were calculated.
Differences were evaluated by using the t test and non-parametric
Mann–Whitney test, with po0.05 considered statistically
significant.
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